Exelixis Inc (NASDAQ: EXEL)’s stock price has increased by 1.58 compared to its previous closing price of 23.35. However, the company has seen a 1.63% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-09 that Investors interested in Medical – Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
Is It Worth Investing in Exelixis Inc (NASDAQ: EXEL) Right Now?
Exelixis Inc (NASDAQ: EXEL) has a price-to-earnings ratio of 36.65x that is above its average ratio. Additionally, the 36-month beta value for EXEL is 0.57. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for EXEL is 294.81M and currently, short sellers hold a 2.80% ratio of that float. The average trading volume of EXEL on April 10, 2024 was 2.30M shares.
EXEL’s Market Performance
EXEL stock saw an increase of 1.63% in the past week, with a monthly gain of 6.80% and a quarterly increase of 5.24%. The volatility ratio for the week is 2.13%, and the volatility levels for the last 30 days are 1.98% for Exelixis Inc (EXEL). The simple moving average for the last 20 days is 1.49% for EXEL stock, with a simple moving average of 9.83% for the last 200 days.
Analysts’ Opinion of EXEL
Many brokerage firms have already submitted their reports for EXEL stocks, with BTIG Research repeating the rating for EXEL by listing it as a “Buy.” The predicted price for EXEL in the upcoming period, according to BTIG Research is $27 based on the research report published on December 19, 2023 of the previous year 2023.
Citigroup, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $31. The rating they have provided for EXEL stocks is “Buy” according to the report published on December 15th, 2023.
H.C. Wainwright gave a rating of “Buy” to EXEL, setting the target price at $28 in the report published on September 26th of the previous year.
EXEL Trading at 6.94% from the 50-Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.55% of loss for the given period.
Volatility was left at 1.98%, however, over the last 30 days, the volatility rate increased by 2.13%, as shares surge +5.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.23% upper at present.
During the last 5 trading sessions, EXEL rose by +1.63%, which changed the moving average for the period of 200-days by +19.32% in comparison to the 20-day moving average, which settled at $23.44. In addition, Exelixis Inc saw -1.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXEL starting from Garber Alan M, who sale 19,205 shares at the price of $24.01 back on Mar 21 ’24. After this action, Garber Alan M now owns 35,703 shares of Exelixis Inc, valued at $461,112 using the latest closing price.
Haley Patrick J., the EVP, Commercial of Exelixis Inc, sale 47,020 shares at $21.45 during a trade that took place back on Feb 23 ’24, which means that Haley Patrick J. is holding 384,866 shares at $1,008,579 based on the most recent closing price.
Stock Fundamentals for EXEL
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.96 for the gross margin
The net margin for Exelixis Inc stands at 0.11. The total capital return value is set at 0.06. Equity return is now at value 8.74, with 6.85 for asset returns.
Based on Exelixis Inc (EXEL), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 1.55. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -6.24.
Currently, EBITDA for the company is 196.6 million with net debt to EBITDA at -0.41. When we switch over and look at the enterprise to sales, we see a ratio of 3.89. The receivables turnover for the company is 7.71for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.
Conclusion
In conclusion, Exelixis Inc (EXEL) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
